Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus COR OTICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus COR OTICIN.
CHLOROMYXIN vs COR-OTICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
1-2 drops in each affected ear twice daily for 7 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
CHLOROMYXIN is not a recognized drug. No data available.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Category C
Category C
Antibiotic
Topical Corticosteroid + Antibiotic